Assertio Therapeutics (ASRT) Tops Q3 EPS by 16c; Raises FY EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Assertio Therapeutics Announces Third-Quarter 2018 Financial Results
November 8, 2018 4:06 PM EST-- Confirms Full-Year Net Sales Guidance Range for the Neurology Franchise ---- Raises Full-Year Earnings Guidance and Confirms Adjusted EBITDA Guidance ---- Amends and Strengthens Commercial Agreement with Collegium ---- Confirms Regulatory Plan to File for FDA Approval of Cosyntropin Depot by Year End --
LAKE FOREST, Ill., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today reported financial results for the quarter ended September 30, 2018, and provided an update on its business performance and strategic initiatives.
Our third-quarter performance positions us well to... More
